Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer

• Published in: Cancers 2020-10, Vol.12 (10), p.2882
• Main Authors: Vacher, Sophie, Suybeng, Voreak, Girard, Elodie, Masliah Planchon, Julien, Thomson, Grégory, Le Goux, Constance, Garinet, Simon, Schnitzler, Anne, Chemlali, Walid, Firlej, Virginie, Damotte, Diane, Allory, Yves, Kamal, Maud, Pignot, Géraldine, Bieche, Ivan
• Format: Article
• Language: English
• Subjects: Biomarkers; Bladder cancer; Cancer; Carcinogenesis; Cell cycle; Cytosine; Gene expression; Gene mutations; Genetic aspects; Genomes; Genomic instability; Guanine; Head & neck cancer; Health aspects; Immunotherapy; Interferon; Life Sciences; Medical prognosis; Metastasis; Microsatellite instability; Mutation; Polymerase chain reaction; Prostate; Proteins; Squamous cell carcinoma; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12102882

Numerous pan-genomic studies identified alterations in protein-coding genes and signaling pathways involved in bladder carcinogenesis, while non-coding somatic alterations remain weakly explored. The goal of this study was to identify clinical biomarkers in non-coding regions for bladder cancer patients. We have previously identified in bladder tumors two non-coding mutational hotspots occurring at high frequencies (≥30%). These mutations are located close to the GPR126 and PLEKHS1 genes, at the guanine or the cytosine of a TGAACA core motif flanked, on both sides, by a stretch of palindromic sequences. Here, we hypothesize that such a pattern of recurrent non-coding mutations could be a signature of somatic genomic instability specifically involved in bladder cancer. We analyzed 26 additional mutable non-coding sites with the same core motif in a cohort of 103 bladder cancers composed of 44 NMIBC cases and 59 MIBC cases using high-resolution melting (HRM) and Sanger sequencing. Five bladder cancers were additionally analyzed for protein-coding gene mutations using a targeted NGS panel composed of 571 genes. Expression levels of three members of the APOBEC3 family genes were assessed using real-time quantitative RT-PCR. Non-coding somatic mutations were observed for at least one TGAACA core motif locus in 62.1% (64/103) of bladder tumor samples. These non-coding mutations co-occurred in the bladder tumors but were absent in prostate tumor, HPV-positive Head and Neck Squamous Cell Carcinoma, and high microsatellite instability (MSI-H) colorectal tumor series. This signature of palindromic non-coding somatic mutations, specific to bladder tumors, was not associated with patients’ outcome and was more frequent in females. Interestingly, this signature was associated with high tumor mutational burden (TMB) and high expression levels of APOBEC3B and interferon inducible genes. We identified a new type of somatic genomic instability targeting the TGAACA core motif loci flanked by palindromic sequences in bladder cancer. This mutational signature is a promising candidate clinical biomarker for the early detection of relapse and a major low-cost alternative to the TMB to monitor the response to immunotherapy for bladder cancer patients.